Bruno Lucidi leaves Karolinska
This article was originally published in Scrip
Stockholm-based Karolinska Development has announced that CEO Bruno Lucidi has left the company, less than four months after his permanent appointment to the position. Mr Lucidi's departure has been chalked-up to a "difference of opinion" between the former CEO and the company's board or directors over the implementation of the company's strategy. He has been replaced by deputy CEO Terje Kalland until a new, permanent CEO can be appointed, the company said. Karolinska has begun a search for a permanent successor. Mr Lucidi is also stepping down as CEO for KDev Oncology and Karolinska Development's portfolio companies Aprea and Akinion Pharmaceuticals.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.